KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbCellera Biologics (ABCL) EBT (2020 - 2026)

AbCellera Biologics filings provide 7 years of EBT readings, the most recent being -$49.5 million for Q1 2026.

  • Quarterly EBT rose 6.51% to -$49.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$174.1 million through Mar 2026, up 17.32% year-over-year, with the annual reading at -$177.6 million for FY2025, 11.38% up from the prior year.
  • EBT hit -$49.5 million in Q1 2026 for AbCellera Biologics, down from -$19.5 million in the prior quarter.
  • Across five years, EBT topped out at $230.8 million in Q1 2022 and bottomed at -$68.8 million in Q3 2025.
  • Average EBT over 5 years is -$21.3 million, with a median of -$42.7 million recorded in 2024.
  • The largest annual shift saw EBT surged 286.56% in 2022 before it crashed 451.9% in 2023.
  • AbCellera Biologics' EBT stood at -$31.4 million in 2022, then plummeted by 54.72% to -$48.6 million in 2023, then grew by 3.65% to -$46.8 million in 2024, then skyrocketed by 58.36% to -$19.5 million in 2025, then tumbled by 154.05% to -$49.5 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's EBT are -$49.5 million (Q1 2026), -$19.5 million (Q4 2025), and -$68.8 million (Q3 2025).